Douglas R Martin

List of Publications by Year
in descending order

48 papers	1,575 citations	257450 24 h-index	315739 38 g-index
50 all docs	50 docs citations	50 times ranked	1591 citing authors

#	Article	IF	Citations
1	Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis. Brain, 2022, 145, 655-669.	7.6	7
2	AAV gene therapy for Tay-Sachs disease. Nature Medicine, 2022, 28, 251-259.	30.7	49
3	Whole-Genome Shotgun Metagenomic Sequencing Reveals Distinct Gut Microbiome Signatures of Obese Cats. Microbiology Spectrum, 2022, 10, e0083722.	3.0	15
4	Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease. Gene Therapy, 2021, 28, 142-154.	4.5	7
5	GM1 Gangliosidosis: Mechanisms and Management. The Application of Clinical Genetics, 2021, Volume 14, 209-233.	3.0	29
6	Natural history of Tay-Sachs disease in sheep. Molecular Genetics and Metabolism, 2021, 134, 164-174.	1.1	2
7	White Matter Pathology as a Barrier to Gangliosidosis Gene Therapy. Frontiers in Cellular Neuroscience, 2021, 15, 682106.	3.7	2
8	Real-time MR tracking of AAV gene therapy with Î²gal-responsive MR probe in a murine model of GM1-gangliosidosis. Molecular Therapy - Methods and Clinical Development, 2021, 23, 128-134.	4.1	8
9	A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. Molecular Therapy, 2020, 28, 411-421.	8.2	58
10	7T MRI Predicts Amelioration of Neurodegeneration in the Brain after AAV Gene Therapy. Molecular Therapy - Methods and Clinical Development, 2020, 17, 258-270.	4.1	15
11	Abnormal epiphyseal development in a feline model of Sandhoff disease. Journal of Orthopaedic Research, 2020, 38, 2580-2591.	2.3	2
12	Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice. Molecular Therapy, 2020, 28, 2150-2160.	8.2	16
13	Amylin and pramlintide modulate Î³-secretase level and APP processing in lipid rafts. Scientific Reports, 2020, 10, 3751.	3.3	6
14	Whole-slide image analysis outperforms micrograph acquisition for adipocyte size quantification. Adipocyte, 2020, 9, 567-575.	2.8	12
15	PEA15 loss of function and defective cerebral development in the domestic cat. PLoS Genetics, 2020, 16, e1008671.	3.5	4
16	Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses. PLoS ONE, 2020, 15, e0243006.	2.5	3
17	PEA15 loss of function and defective cerebral development in the domestic cat. , 2020, 16, e1008671.		0
18	PEA15 loss of function and defective cerebral development in the domestic cat. , 2020, 16, e1008671.		0

#	Article	IF	Citations
19	PEA15 loss of function and defective cerebral development in the domestic cat. , 2020, 16, e1008671.		0
20	PEA15 loss of function and defective cerebral development in the domestic cat. , 2020, 16, e1008671.		0
21	Adeno-Associated Virus Gene Therapy in a Sheep Model of Tayâ€“Sachs Disease. Human Gene Therapy, 2018, 29, 312-326.	2.7	61
22	Direct Intracranial Injection of AAVrh8 Encoding Monkey Î²-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain. Human Gene Therapy, 2017, 28, 510-522.	2.7	66
23	Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model. Molecular Therapy, 2017, 25, 892-903.	8.2	36
24	Lipidomic Evaluation of Feline Neurologic Disease after AAV Gene Therapy. Molecular Therapy - Methods and Clinical Development, 2017, 6, 135-142.	4.1	17
25	Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy. Nanomedicine, 2017, 12, 2591-2606.	3.3	32
26	AAV-mediated gene delivery attenuates neuroinflammation in feline Sandhoff disease. Neuroscience, 2017, 340, 117-125.	2.3	20
27	Emerging therapies for neuropathic lysosomal storage disorders. Progress in Neurobiology, 2017, 152, 166-180.	5.7	25
28	Animal models of GM2 gangliosidosis: utility and limitations. The Application of Clinical Genetics, 2016, Volume 9, 111-120.	3.0	28
29	In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy. Molecular Therapy, 2016, 24, 1247-1257.	8.2	98
30	Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector. Molecular Therapy, 2016, 24, 726-735.	8.2	93
31	Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy. Molecular Genetics and Metabolism, 2015, 116, 80-87.	1.1	27
32	Bis(monoacylglycero)phosphate: a secondary storage lipid in the gangliosidoses. Journal of Lipid Research, 2015, 56, 1005-1006.	4.2	54
33	AAV-Mediated Gene Delivery in a Feline Model of Sandhoff Disease Corrects Lysosomal Storage in the Central Nervous System. ASN Neuro, 2015, 7, 175909141556990.	2.7	47
34	Molecular cloning, sequencing, and distribution of feline GnRH receptor (GnRHR) and resequencing of canine GnRHR. Theriogenology, 2015, 83, 266-275.	2.1	1
35	Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease. Experimental Neurology, 2015, 263, 102-112.	4.1	26
36	AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement. Neuromethods, 2015, , 265-295.	0.3	5

#	Article	IF	Citations
37	Sustained Normalization of Neurological Disease after Intracranial Gene Therapy in a Feline Model. Science Translational Medicine, 2014, 6, 231ra48.	12.4	56
38	High resolution MRI anatomy of the cat brain at 3Tesla. Journal of Neuroscience Methods, 2014, 227, 10-17.	2.5	35
39	Ganglioside Storage Diseases: On the Road to Management. Advances in Neurobiology, 2014, 9, 485-499.	1.8	7
40	Therapeutic Response in Feline Sandhoff Disease Despite Immunity to Intracranial Gene Therapy. Molecular Therapy, 2013, 21, 1306-1315.	8.2	71
41	Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy. Molecular Genetics and Metabolism, 2012, 107, 203-212.	1.1	41
42	Comparative Analysis of Brain Lipids in Mice, Cats, and Humans with Sandhoff Disease. Lipids, 2009, 44, 197-205.	1.7	47
43	Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase Î²-subunit deficiency. Molecular Genetics and Metabolism, 2009, 97, 53-59.	1.1	47
44	Generation and characterization of recombinant feline Î²-galactosidase for preclinical enzyme replacement therapy studies in GM1 gangliosidosis. Metabolic Brain Disease, 2008, 23, 161-173.	2.9	15
45	Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis. Molecular Genetics and Metabolism, 2008, 94, 212-221.	1.1	36
46	Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis. Acta Neuropathologica, 2005, 110, 443-450.	7.7	47
47	An inversion of 25 base pairs causes feline G M2 gangliosidosis variant 0. Experimental Neurology, 2004, 187, 30-37.	4.1	54
48	Isolation and characterization of multipotential mesenchymal stem cells from feline bone marrow. Experimental Hematology, 2002, 30, 879-886.	0.4	245